De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Guardant Health Toekomstige groei

Future criteriumcontroles 1/6

Guardant Health zal naar verwachting groeien in winst en omzet met respectievelijk 18.4% en 17% per jaar. De winst per aandeel zal naar verwachting groeien met 19.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -182.3% zijn.

Belangrijke informatie

18.4%

Groei van de winst

19.2%

Groei van de winst per aandeel

Healthcare winstgroei	19.3%
Inkomstengroei	17.0%
Toekomstig rendement op eigen vermogen	-182.3%
Dekking van analisten	Good
Laatst bijgewerkt	30 Sep 2024

Recente toekomstige groei-updates

Recent updates

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 24

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Aug 21

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Jul 31

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jul 12

Guardant: Double-Digit Sales Projections Come At A Cost

Jun 06

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Jun 04

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

May 14

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Mar 29

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21

Winst- en omzetgroeiprognoses

NasdaqGS:GH - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1,002	-283	-257	-189	14
12/31/2025	825	-343	-273	-208	22
12/31/2024	695	-390	-300	-243	22
6/30/2024	644	-491	-299	-281	N/A
3/31/2024	604	-461	-301	-281	N/A
12/31/2023	564	-479	-345	-325	N/A
9/30/2023	536	-432	-363	-337	N/A
6/30/2023	510	-508	-383	-337	N/A
3/31/2023	482	-665	-418	-355	N/A
12/31/2022	450	-655	-387	-309	N/A
9/30/2022	431	-606	-388	-296	N/A
6/30/2022	408	-551	-363	-271	N/A
3/31/2022	391	-419	-309	-221	N/A
12/31/2021	374	-406	-284	-209	N/A
9/30/2021	344	-409	-249	-191	N/A
6/30/2021	324	-379	-191	-146	N/A
3/31/2021	298	-336	-143	-107	N/A
12/31/2020	287	-254	-158	-104	N/A
9/30/2020	271	-185	-129	-75	N/A
6/30/2020	258	-120	-118	-66	N/A
3/31/2020	245	-77	-102	-56	N/A
12/31/2019	214	-76	-68	-47	N/A
9/30/2019	184	-76	-60	-43	N/A
6/30/2019	145	-87	-81	-67	N/A
3/31/2019	111	-97	-89	-70	N/A
12/31/2018	91	-85	-92	-72	N/A
9/30/2018	78	-75	-85	-64	N/A
6/30/2018	67	-84	-87	-68	N/A
3/31/2018	57	-83	N/A	-65	N/A
12/31/2017	50	-89	N/A	-72	N/A
12/31/2016	25	-46	N/A	-37	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat GH de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat GH de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat GH de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van GH ( 17% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van GH ( 17% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat GH binnen 3 jaar verliesgevend zal zijn.

Guardant Health Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.0% to US$41.85

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

Price target decreased by 7.1% to US$42.94

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Recent updates

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Price target increased by 7.0% to US$41.85

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

High number of new directors

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Guardant: Double-Digit Sales Projections Come At A Cost

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Price target decreased by 7.1% to US$42.94

Full year 2023 earnings: EPS misses analyst expectations

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Guardant Health, Inc. to Appeal Federal District Court Verdict

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Now 20% undervalued after recent price drop

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Consensus estimates of losses per share improve by 14%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Price target decreased by 7.1% to US$52.82

Guardant Health, Inc. Announces Management Changes

Chief Legal Officer exercised options and sold US$90k worth of stock

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

High number of new directors

Co-CEO & Director recently bought US$2.5m worth of stock

Chief Information Officer recently sold US$193k worth of stock

Consensus EPS estimates upgraded to US$4.60 loss, revenue downgraded

Full year 2022 earnings: EPS misses analyst expectations

Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer

Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer

Price target decreased by 8.4% to US$63.56

Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery

Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer